Harlan Contract Research Services and Bertin Pharma, headquartered in Montigny-le-Bretonneux, France, have entered a strategic partnership to offer comprehensive services for early drug development. The companies will offer a wider range of drug discovery and translational medicine services, including expanded profiling and molecule testing, particularly in the context of regulatory studies. Harlan CRS will provide its drug discovery and translational medicine offerings using Bertin Pharma’s expertise in immunology and biomarkers.
 
“The new agreement benefits us both strategically and scientifically,” said Ciriaco Maraschiello, director of strategic initiatives and director of drug discovery and translational medicine at Harlan CRS. “Working together, we will provide the pharmaceutical industry the best team of scientists to increase the likelihood of success for new generation drugs.”
 
“For Bertin Pharma, this partnership will increase our international visibility and allow us to expand our services by integrating project management capabilities and expertise,” said Xavier Morge, managing director of Bertin Pharma.